High mobility group box 1 levels in on and off-pump cardiac surgery patients

International Heart Journal

Volumn 52, Issue 3, 2011, Pages 170-174

  Haque, Anwarul ^a   Kunimoto, Fumio ^b   Narahara, Hajime ^b   Okawa, Makio ^b   Hinohara, Hiroshi ^b   Kurabayashi, Masahiko ^a   Saito, Shigeru ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; HMGB1; Off pump coronary artery bypass

Indexed keywords

C REACTIVE PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AGED; AORTA CLAMPING; ARTICLE; CARDIOPULMONARY BYPASS; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; IMMUNOCOMPETENT CELL; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; MALE; OFF PUMP CORONARY SURGERY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURGICAL PATIENT; TISSUE PERFUSION;

AGED; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY BYPASS; CORONARY ARTERY BYPASS, OFF-PUMP; CYTOKINES; FEMALE; HMGB1 PROTEIN; HUMANS; MALE;

EID: 79958758198     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.170     Document Type: Article

References (27)

1. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
2. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-570.
3. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003; 254: 375-85.
4. Fink M P. Bench-to-bedside review: High-mobility group box 1 and critical illness. Crit Care 2007; 11: 229.
5. Yang H, Wang H, Tracey KJ. HMG-1 rediscovered as a cytokine. Shock 2001; 15: 247-253. (Review)
6. Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005; 94: 975-979.
7. Yasuda T, Ueda T, Takeyama Y, et al. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006; 33: 359-563.
8. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33: 564-573.
9. Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 2008; 34: 1046-1053.
10. Peltz ED, Moore EE, Eckels PC, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 2009; 32: 17-22.
11. Cohen MJ, Brohi K, Calfee CS, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care 2009; 13: R174.
12. Levy RM, Mollen KP, Prince JM, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1538-R1544.
13. Goldstein RS, Gallowitsch-Puerta M, Yang L, et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocar-dial ischemia. Shock 2006; 25: 571-574.
14. Cirillo P, Giallauria F, Pacileo M, et al. Increased high mobility group box-1 protein levels are associated with impaired cardiopul-monary and echocardiographic findings after acute myocardial infarction. J Card Fail 2009; 15: 362-367.
15. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997; 85: 766-782. (Review)
16. Roth-Isigkeit A, Borstel T V, Seyfarth M, Schmucker P. Periopera-tive serum levels of tumour-necrosis-factor alpha (TNF-alpha), IL-1beta, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution. Clin Exp Immunol 1999; 118: 242-246.
17. Westaby S. Organ dysfunction after cardiopulmonary bypass. A systemic infammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 1987; 13: 89-95. (Review)
18. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly puri-fed eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007; 81: 49-58.
19. Borden EC, Chin P. Interleukin-6: a cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 1994; 123: 824-829. (Review)
20. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 1991; 91: 23-29.
21. Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-362.
22. Shalaby MR, Waage A, Aarden L, Espevik T. Endotoxin, tumour necrosis factor-alpha and interleukin 1 induces interleukin 6 production in vivo. Clin Immunol Immunopathol 1989; 53: 488-498.
23. Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced gly-cation end product (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 1994; 91: 8807-8811.
24. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by mono-cytes. J Exp Med 1991; 174: 1209-1220.
25. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-3822.
26. Thompson D, Milford-Ward A, Whicher JT. The value of acute phase protein measurements in clinical practice. Ann Clin Bio-chem 1992; 29: 123-131. (Review)
27. Pepys MB. C-reactive protein ffty years on. Lancet 1981; 1: 653-657.